A61K 40/4235
Interferons [ifn]
Official title: {Interferons [IFN]}
A61K40/4235 (Interferons [ifn]) appears on 14 US grants and 30 published applications in this corpus.
Search patents in A61K- Granted patents
- 14
- Published applications
- 30
- Assignees
- 24
- Inventors
- 71
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 3 |
| 2003 | 0 | 1 |
| 2004 | 0 | 4 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 1 |
| 2022 | 2 | 4 |
| 2023 | 1 | 0 |
| 2024 | 0 | 3 |
| 2025 | 1 | 4 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Constructs for chimeric antigen receptors14 Apr 2026US 12,600,796 B2Carisma Therapeutics Inc.
- Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand4 Mar 2025US 12,239,666 B2H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor29 Aug 2023US 11,739,297 B2Carisma Therapeutics Inc.
- Compositions and methods for TCR reprogramming using fusion proteins5 Jul 2022US 11,377,638 B2Tcr2 Therapeutics Inc.
- Constructs for chimeric antigen receptors26 Apr 2022US 11,312,939 B2Carisma Therapeutics Inc.
- Therapeutic base editing30 Jul 2026US 2026/0216245 A1The J. David Gladstone Institute, A Testamentary Trust Established Under the Will of J. David Gladst
- Human ifn-alpha2 and pd-l1 overexpressing t cells for immune modulation of autoimmune and alloimmune disorders11 Jun 2026US 2026/0158068 A1Hackensack Meridian Health Center for Discovery and Innovation
- Armed chimeric receptors and methods of use thereof28 May 2026US 2026/0144818 A1Senti Biosciences, Inc.
- Treatment of mhc-i negative tumors with nk and t cells5 Feb 2026US 2026/0034214 A1ImmunityBio, Inc.
- Compositions and Methods for Treating Cancer and Viral Infections11 Sep 2025US 2025/0282846 A1
Most cited
By later US patents
- Compositions and methods for TCR reprogramming using fusion proteins11US 10,208,285 B2Tcr2 Therapeutics Inc. · 2019
- Generation and use of dendritic cells8US 7,405,076 B2Universite Libre de Bruxelles · 2008
- Methods and compositions for obtaining mature dendritic cells4US 7,198,948 B2Argos Therapeutics, Inc. · 2007
- T-cell therapy to neurodegenerative diseases3US 10,117,895 B2Ben-Gurion University of the Negev Research and Development Authority · 2018
- Method of preparing activated killer monocytes for treating colorectal cancer3US 5,093,115 AThe United States of America as represented by the Department of Health and Human Services · 1992